|
A new class of
anti-clotting drugs that may be more effective than
aspirin at preventing disease-causing blood clots
(thrombus) and has fewer side effects has been
developed by a team at Melbourne's Monash
University with Cerylid Biosciences Ltd.
Thrombus or clots are formed due to platelets
normally floating in the blood reacting
to a cascade of biochemicals from an injury
causing the formation of fibrin that allow
blood cells to clot together.
The new drug works on the biochemicals that detect
clots forming due to increased pressure(shear
stress) often due to fatty
deposits along blood vessels which is
different to the type of injury that causes usual
bleeding.
Dr Shaun Jackson from Monash Univeristy, told
Clearlyexplained.Com news that " One of the major
factors regulating pathological thrombus formation
is shear stress." he further explained
that "platelets can become activated by
the blood flow itself".
This new class of drug called PI-Kinase inhibitors
stops this from occuring. Dr.
Jackson said that " The PI 3-kinase inhibitors
we have developed effectively inhibit shear-induced
platelet activation"
When a person suffers a normal cut this
shear-induced situation does not occur and so this
drug does not have a significant impact on the
normal clotting process.
|

Aspirin works as an effective
anti-clotting agent but has some side effects such
as increased bleeding.
"Aspirin is the most widely used
anti-clotting drug , however it is only effective
at preventing fatal heart attack and stroke for
about one in four patients," Dr Jackson told Monash
Univeristy. "There is a major need for safer and
more effective anti-clotting drugs. The 'holy
grail' in the field is a drug that prevents
disease-causing clots whilst not increasing the
risk of bleeding.
First trials in human volunteers
have yielded promising results.
|